Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable or chronic diseases that do not respond adequately to more conventional treatments. In many cases, these treatments are curative, making them life altering and even lifesaving.

While the onus is on Contract Development and Manufacturing Organizations (CDMOs), such as Almac Pharma Services, to handle these products correctly, drug manufacturers should be aware of the risks and complications involved in every step of the supply chain. They must ensure that their CDMO has the expertise to control for, and mitigate against, the risks.

Download the article to find out more.